A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1879 participants.

Also called NCT03987919

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,879 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03987919
  • EudraCT 2018-004422-29
Other papers using this trial's data
  • Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022-09 DOI, PubMed 35489606, PMC9046133 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England journal of medicine, 2021-08-05 DOI, PubMed 34170647

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Israel, Mexico, Puerto Rico, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03987919. Randomized; no masking; primary purpose treatment. Start 2019-07-30 (actual); primary completion 2021-01-28 (actual). Results posted on 2022-02-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Acronym
SURPASS-2
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Semaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03987919
Content hash
2c1a6b90d203851f9e20ed26902af6c2d990cebf6006262ff336cd80112c3492